Am J Psychiatry 163:1273-1276, July 2006
doi: 10.1176/appi.ajp.163.7.1273
© 2006 American Psychiatric Association
Prevalence of the Metabolic Syndrome Among Patients Receiving Clozapine
J. Steven Lamberti, M.D.,
David Olson, Ph.D., R.Ph.,
John F. Crilly, M.S.W., Ph.D.,
Telva Olivares, M.D.,
Geoffrey C. Williams, M.D., Ph.D.,
Xin Tu, Ph.D.,
Wan Tang, Ph.D.,
Karen Wiener, M.D.,
Steven Dvorin, M.D., and
Marci B. Dietz, M.S., R.N.
OBJECTIVE: This study compared the prevalence of the metabolic syndrome among outpatients with schizophrenia and schizoaffective disorder receiving clozapine with a matched comparison group from the National Health and Nutrition Examination Survey. METHOD: Ninety-three outpatients and a matched group of 2,701 comparison subjects were compared according to National Cholesterol Education Program criteria. Outpatient data were obtained through physical assessments, laboratory testing, and reviews of medical records. RESULTS: The prevalence of the metabolic syndrome was significantly higher among clozapine patients (53.8%) than among the comparison group (20.7%). For clozapine patients, logistic regression analysis revealed significant associations with age, body mass index, and duration of clozapine treatment. Only age and body mass index were associated with the prevalence of metabolic syndrome in both groups. CONCLUSIONS: Patients receiving clozapine are at significantly increased risk for developing the metabolic syndrome. Psychiatrists and other providers should consider performing regular physical health monitoring to prevent long-term adverse health consequences.
Related Article:
-
In This Issue
Am J Psychiatry 2006 163: A58.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
D. Morgan, M. Sargeant, J. Chukwuma, and G. Hughes
Audit of metabolic syndrome in adults prescribed clozapine in community and long-stay in-patient populations
Psychiatr. Bull.,
May 1, 2008;
32(5):
174 - 177.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Dickinson, J. M. Gold, F. B. Dickerson, D. Medoff, and L. B. Dixon
Evidence of Exacerbated Cognitive Deficits in Schizophrenia Patients With Comorbid Diabetes
Psychosomatics,
April 1, 2008;
49(2):
123 - 131.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Terre
Behavioral Medicine Review: Psychological Risks for Metabolic Syndrome
American Journal of Lifestyle Medicine,
April 1, 2008;
2(2):
126 - 129.
[Abstract]
[PDF]
|
|
|
|
|
|
|
W. S. Fenton and M. R. Chavez
Medication-Induced Weight Gain and Dyslipidemia in Patients With Schizophrenia
Focus,
January 1, 2008;
6(2):
246 - 253.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Ojala, E. Repo-Tiihonen, J. Tiihonen, and L. Niskanen
Statins are effective in treating dyslipidemia among psychiatric patients using second-generation antipsychotic agents
J Psychopharmacol,
January 1, 2008;
22(1):
33 - 38.
[Abstract]
[PDF]
|
|
|
|
|
|
|
W. V. Zhang, I. Ramzan, and M. Murray
Impaired Microsomal Oxidation of the Atypical Antipsychotic Agent Clozapine in Hepatic Steatosis
J. Pharmacol. Exp. Ther.,
August 1, 2007;
322(2):
770 - 777.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. K. Erickson, J. R. Ciccone, S. B. Schwarzkopf, J. S. Lamberti, and M. J. Vitacco
Legal Fallacies of Antipsychotic Drugs
J Am Acad Psychiatry Law,
June 1, 2007;
35(2):
235 - 246.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. S. Fenton and M. R. Chavez
Medication-Induced Weight Gain and Dyslipidemia in Patients With Schizophrenia
Am J Psychiatry,
October 1, 2006;
163(10):
1697 - 1704.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. I. Holt
Review: Severe mental illness, antipsychotic drugs and the metabolic syndrome
The British Journal of Diabetes & Vascular Disease,
September 1, 2006;
6(5):
199 - 204.
[Abstract]
[PDF]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 2006
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
